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Cardiovascular disease is predicted to be the
commonest cause of death worldwide by the year
2020. Diabetes, smoking and hypertension are the
main risk factors. The renin-angiotensin system plays
a key role in regulating blood pressure and fluid and
electrolyte homeostasis in mammals. The discovery
of specific drugs that block either the key enzyme of
the renin-angiotensin system, angiotensin-convert-
ing enzyme (ACE), or the receptor for its main effec-
tor angiotensin II, was a major step forward in the
treatment of hypertension and heart failure. In recent
years, however, the renin-angiotensin system has
been shown to be a far more complex system than
initially thought. It has become clear that additional
peptide mediators are involved. Furthermore, a new
ACE, angiotensin-converting enzyme 2 (ACE2), has
been discovered which appears to negatively regu-
late the renin-angiotensin system. In the heart, ACE2
deficiency results in severe impairment of cardiac
contractility and upregulation of hypoxia-induced
genes. We shall discuss the interplay of the various
effector peptides generated by angiotensin-convert-
ing enzymes ACE and ACE2, highlighting the role of
ACE2 as a negative regulator of the renin-angiotensin
system.
Introduction
The renin-angiotensin system is a complex regulatory
system that plays a key role in maintaining blood
pressure homeostasis, as well as fluid and salt
balance in mammals [1–4]. The angiotensin convert-
ing-enzyme (ACE) is an important regulator of the
renin-angiotensin system. Recently, a homologue of
human ACE, angiotensin-converting enzyme 2 (ACE2),
has been discovered [5,6]. Characterisation of its
function and substrate specificity [5,6], together with
data from ace2 mutant mice [7], suggests that ACE2
negatively regulates the activated renin-angiotensin
system. In this review we shall discuss the functions
of ACE and ACE2 and their substrates and products in
the regulation of the renin-angiotensin system.
Classical Model of the Renin-Angiotensin System
In the classical pathway of the renin-angiotensin
system, activation of a cascade of enzymatic reactions
results in the generation of the main effector molecule
angiotensin II, which acts both as a systemic and a
locally generated paracrine or autocrine effector
peptide [1–3] (Figure 1). The protease renin, which is
secreted by juxtaglomerular cells at the renal afferent
arterioles, cleaves the liver-derived precursor peptide
angiotensinogen into the decameric peptide angio-
tensin I. Angiotensin I is further hydrolyzed into the
vasoconstrictor octapeptide angiotensin II by the pro-
teolytic dipeptidase ACE, located on the luminal side
of the vascular endothelium, and other non-ACE
systems, such as tissue chymase at the tissue level [8].
ACE also inactivates the vasodilator peptides
bradykinin and kallidin. Thus, activation of the renin-
angiotensin system mainly results in a systemic vaso-
pressor response by blocking the hypotensive
kinin-bradykinin pathway and by generation of the
vasoconstrictor angiotensin II [4].
Angiotensin II is not just a potent vasopressor which
raises systemic blood pressure; it also mediates a
broad array of physiological and pathophysiological
effects by binding to specific cell membrane receptors
[9,10]. So far, two distinct types of G-protein-coupled
receptors for angiotensin II have been cloned and char-
acterised in humans and rodents. The angiotensin II
type 1 (AT1) and type 2 (AT2) receptors are heteroge-
neously distributed in peripheral tissues and the brain
[9,10]. The AT1 receptor is predominantly expressed in
the kidneys, adrenal glands, vascular smooth muscle
cells and the heart, and it is to this receptor that the
regulatory actions of angiotensin II on blood pressure
and salt/water balance have been attributed [9,11,12].
The AT2 receptor is present at high density during fetal
development; in the adult, significant AT2 receptor
expression occurs only in the adrenal medulla, uterus,
ovary, vascular endothelium, adrenal glands and certain
areas in the brain [4,9]. The AT2 receptor is thought to
counterbalance effects mediated by the AT1 receptor: it
appears to induce vasodilation and may be involved in
the control of cell proliferation, differentiation and
angiogenesis [4,10,11].
A Broad Array of Biologically Active Peptides
In vivo, angiotensin II is degraded into several meta-
bolites by different enzymes (Figure 2). So far, it has
been shown that at least five of these products are
biologically active [4]. Interestingly, these metabolites
have different biological effects. Angiotensin III, which
is cleaved from angiotensin II by an aminopeptidase,
binds to both AT1 and AT2 receptors and acts similar
to angiotensin II [13]. In contrast, angiotensin(1–7), a
product of angiotensin II as well as of the angiotensin
I metabolite angiotensin(1–9), appears to have vasodi-
latatory [14–16] and antiproliferative effects mediated
by binding a novel, not yet defined, angiotensin(1–7)
receptor [17].
Angiotensin IV is generated from angiotensin III by an
as yet unknown pathway. In the kidneys, angiotensin IV
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enhances natriuresis and increases renal blood flow.
There is evidence that, in the central nervous system,
angiotensin IV facilitates memory retention and retrieval
[4,12]. The effects of angiotensin IV involve a novel AT4
receptor [18,19]. The AT4 receptor has also been iden-
tified as an insulin-regulated aminopeptidase [19], sug-
gesting an indirect mechanism whereby angiotensin IV
might extend the half-life of biologically active neu-
ropeptides by competitive inhibition of AT4’s enzyme
activity [4,19].
The diversity of the renin-angiotensin system is not
only demonstrated by the different effects of the
various degradation products of angiotensin I and
angiotensin II. Characterisation of receptor specificities
and enzymes involved in the degradation of angiotensin
metabolites has revealed far more complex mediator
systems than previously recognised. It appears that the
complexity of the renin-angiotensin system guarantees
well-tuned adaptation of the blood supply of the body
compartments and organs to all possible physiologic
conditions. In this complex system, a key role has been
attributed to the rate-limiting enzymes, ACE and ACE2,
via their action in generating or degrading the various
active mediators.
Angiotensin Converting-Enzyme (ACE)
ACE was termed a ‘hypertensin-converting enzyme’
when it was initially isolated in 1956 [20]. The human
ace gene, located on chromosome 17, encodes a
180 kDa protein with two homologous domains. Each
domain has an active zinc-binding motif, His-Glu-X-X-
His, which is found in many peptidases [3,21] (Figure
3). ACE is anchored to the plasma membrane through
a single carboxy-terminal transmembrane domain. In
humans, two distinct ACE isoenzymes have been
described, an abundant somatic form found on the
endothelial surface of the lungs and on brush-border
membranes of kidneys, intestine, placenta and
choroid plexus, and the germinal form of ACE found
only in the testis [4]. The function of the germinal form
of ACE remains unclear, but the fact that fertility is
impaired in ace-deficient mice [22,23], but not in AT1A
receptor knock-out mice [24], suggests that testicular
ACE does not mediate its effects via angiotensin
II–AT1A interactions. Both ACE isoforms are mem-
brane-bound protein and, at the cell surface, they
function as ectoenzymes which hydrolyze circulating
peptides. ACE may be cleaved from the cell surface
and act as a soluble enzyme, but the biological signif-
icance of soluble ACE remains unclear.
ACE is currently thought to have two major activities:
it acts as a peptidyl dipeptidase which removes the
carboxy-terminal dipeptide from its substrate, and as
endopeptidase on substrates that are amidated at the
carboxyl terminus (Figure 3). The emerging picture of
ACE function is that it is more than just a key enzyme
that catalyses cleavage of angiotensin I to the potent
vasoconstrictor peptide angiotensin II [3,4,20]. ACE also
hydrolyzes the inactive angiotensin(1-9) peptide into the
vasodilator metabolite angiotensin(1–7) [25], and it is
additionally thought to inactivate the vasodilator pep-
tides bradykinin and kallidin [25,26]. Furthermore, it acts
as endopeptidase on the multi-functional neuropep-
tides substance P and cholecystokinin, and may
degrade the luteinizing hormone releasing hormone
[4,27]. In this context, however, its biological signifi-
cance is not known, nor has the possibility of functional
crosstalk between the systems been excluded.
The finding that ACE catalyzes cleavage of angio-
tensin I into angiotensin II, together with the eluci-
dation of ACE’s three-dimensional structure, led to the
design of specific ACE inhibitors. Inhibition of ACE
results in lowering of blood pressure by impaired for-
mation of angiotensin II and reduced degradation of
the hypotensive peptides bradykinin and kallidin.
Numerous potent ACE inhibitors have been synthe-
sized subsequently and evaluated in clinical trials [28].
Aside from lowering blood pressure, ACE inhibitors
have been found to improve the prognosis of patients
with congestive heart failure and after myocardial
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Figure 1. The renin-angiotensin system:
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infarction [29]. These clinical findings widened our
understanding of the renin-angiotensin system and
suggested that it must have additional functions.
Pharmacological inhibition of ACE by ACE inhibitors
has become a mainstay in treatment of hypertension,
cardiac failure and diabetic nephropathy.
Angiotensin Converting-Enzyme 2
ACE2 has been recently identified as a homolog of
ACE in human, mouse and rat [5–7]; the human ace2
gene has been cloned and mapped to the X chromo-
some [7]. ACE2 is predicted to be a 805 amino acid,
type I membrane-bound glycoprotein with a molecu-
lar weight of about 120 kDa. Like ACE, ACE2 has two
domains: the amino-terminal catalytic domain and the
carboxy-terminal domain (Figure 3). The catalytic
domain has one active site — the zinc metallo-pepti-
dase domain — and shows 41.8% sequence identity
with the amino domain of ACE [4–6]. ACE2’s carboxy-
terminal domain shows 48% sequence identity with
collectrin [30] (Figure 3), a novel renal-specific type 1
transmembrane glycoprotein that lacks the metallo-
protease catalytic domain of ACE and ACE2. In con-
trast to ACE, ACE2 expression appears to be limited
to heart, kidney and testis [6,7]. At the cellular level,
ACE2 is mainly confined to the endothelium and renal
tubular epithelium; occasionally it is identified on vas-
cular smooth muscle cells [6,7].
As an enzyme, ACE2 functions as a carboxy-
monopeptidase with a preference for carboxy-terminal
hydrophobic or basic residues [31]. So whereas ACE
cleaves two amino acids, ACE2 cleaves only the
carboxy-terminal amino acid (Figure 3). Although ACE
and ACE2 share many biochemical properties, ACE2
activity is unaffected by classical ACE inhibitors, such as
captopril or enalaprilat, and its specificity is distinct from
ACE [5,25]. ACE2 hydrolyses angiotensin I, the inactive
precursor of angiotensin II, to generate angiotensin(1–9)
peptides [25,31]. Angiotensin(1-9), in turn, can be con-
verted to the vasodilator peptide angiotensin(1–7) by
ACE. ACE2 also directly converts angiotensin II to
angiotensin(1–7). Angiotensin(1–7) has been proposed to
be an important regulator of cardiovascular function,
promoting vasodilatation, apoptosis and growth arrest
[4,32,33], but the significance of this metabolite in
humans is controversial. Nevertheless, it will be inter-
esting to test whether ACE2 modulates angiotensin II-
mediated effects in the heart and kidneys in vivo by
degradation of angiotensin II and/or the generation of
additional vasodilator peptides.
The specificity of ACE2, like that of ACE, is not
limited to angiotensin I and II. ACE2 also acts on
several other classes of peptides [31] (Figure 2). The
kinin metabolites, des-Arg10-kallidin (des-Arg10-Lys1-
bradykinin) and des-Arg9-bradykinin, but not brady-
kinin, itself are both hydrolyzed by ACE2 [30]. Both of
these metabolites activate the G-protein-coupled B1
receptor [34,35], which is upregulated in response 
to tissue injury and may be important in mediating
inflammatory responses [32], including the local
release of nitric oxide [36].
ACE2 also acts on the peptides apelin-13 and
apelin-36 with high catalytic efficiency [31]. Apelin is
synthesized as 77 amino-acid preprohormone, which
is processed into the 36 amino acid peptide apelin-36;
further proteolytic cleavage generates apelin-13
[37,38]. The physiological role of the apelins is not yet
fully understood [39–41], though apelin-13 has been
shown to promote vasoconstriction in endothelium-
denuded coronary arteries [41] and systemic adminis-
tration of apelin-13 prompts hypotension in rats [42].
Two opioid peptides, dynorphin A (1–13) and β-caso-
morphin, are also substrates of ACE2 [31]. These
peptides activate G-protein-coupled κ and δ opioid
receptors, which regulate pain perception and may
have negative affects on cardiomyocyte contractility
[43–45]. Other substrates for ACE2 include neurotensin
and the related peptide kinetensin, but several other
regulatory peptides, including the enkephalins, are not
ACE2 substrates [31]. Together, the recent findings
suggest a multi-functional role for ACE2, not only in the
renin-angiotensin system, but also in neurotransmis-
sion including pain perception.
Blood Pressure Regulation
Hypertension is recognised to be a major risk factor
for arteriosclerosis [46]. The renin-angiotensin system
has been recognised as the main regulator linking the
extracellular fluid volume to blood pressure homeo-
stasis. Reduction of the perfusion pressure in the
afferent renal arterioles, as a result of a decrease in
either systemic blood pressure or extracellular
volume, or deterioration of renal arteries, results in
reduced glomerular filtration and a decreased amount
of sodium entering the proximal tubuli. In turn, this
stimulates renin secretion in the kidneys. This mecha-
nism, termed tubuloglomerular feedback (reviewed in
[47]), ultimately results in increased angiotensin II
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Figure 2. Amino-acid sequences and ACE (red) and ACE2
(blue) cleavage sites of renin-angiotensin mediator peptides.
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production. Angiotensin II raises systemic blood
pressure by peripheral vasoconstriction and promotes
sodium reabsorption in the kidney, both indirectly by
stimulating aldosterone secretion from the adrenal
cortex and directly by acting on the AT1 receptor [48].
In over 90% of the cases hypertension is considered
to be ‘essential’, in the clinical sense of not having one
distinct cause. Although in a high proportion of these
patients screening of serum aldosterone and plasma
renin activity reveals primary hyperaldosteronism [49],
the etiology of essential hypertension is not yet clear
[46]. Rather, it appears that essential hypertension is
multi-factorial, depending on diet (for example a high
salt diet), environment and genetic factors. 
Several quantitative trait loci (QTL) that affect
susceptibility to hypertension have been identified
[50,51]. The possibility that ACE2 plays a role in
essential hypertension was suggested when ace2 was
mapped to the QTL on the X chromosome in hyper-
tensive rats. This chromosomal region overlaps with
the SS-X QTL in salt-sensitive Sabra rats, the BP3 QTL
in stroke-prone spontaneously hypertensive rats and
the BB.Xs QTL in spontaneous hypertensive rats [7].
In all these rat strains, ACE2 mRNA and protein levels
were found to be greatly reduced and inversely corre-
lated with increased blood pressure [7]. 
These data provide evidence that ACE2 has a role in
the pathogenesis of hypertension. The fact that ACE2
is produced primarily in the heart and the kidneys
reflects the critical role of these organs in controlling
blood pressure homeostasis. But the mechanisms by
which ACE2 regulates blood pressure remain unclear.
Furthermore, collectrin, the ACE2 homolog made
exclusively in kidneys, may play an important role in
controlling ACE /ACE2 functions. Homology searches
of the human genome indicate that the collectrin gene
is located on chromosome Xp22, about 26 kilobases
from the ace2 gene. As collectrin lacks the car-
boxypeptidase domain it may regulate blood pressure
through a process not dependent on angiotensin II.
In vivo models using mice deficient in the key
enzymes renin and ACE, angiotensinogen or the AT1a
receptor have greatly advanced our knowledge of the
renin-angiotensin system and confirmed its role in
blood pressure regulation. Indeed, under physiologi-
cal conditions these mutant mice all show reduced
blood pressure relative to wild-type. Mice deficient in
renin, angiotensinogen or ACE all show altered kidney
morphology and function [22,52], and those deficient
in ACE, angiotensinogen or AT1/AT2 receptors all
show impaired somatic growth [22,52,53].
Mice deficient for the ACE2 gene have recently
been described [7]. These mice develop normally, and
despite the genetic association of ACE2 with
hypertension in rat strains they have normal blood
pressure and renal histology [7]. But levels of the
vasopressor angiotensin II are moderately increased
in the ACE2-deficient mice: so is ACE2 a negative reg-
ulator of blood pressure control in vivo? As ACE2 has
a broad substrate specificity, it cannot be excluded
that in ACE2-deficient mice the hypertensive effects of
elevated angiotensin II levels are blunted by compen-
satory changes in other regulatory peptides, such as
angiotensin(1-7) [32,54], the kinin metabolites [35] or
the newly discovered apelin system [42]. Given that
the susceptibility to essential hypertension is multi-
factorial, it appears that a lack of ACE2 activity pre-
disposes to, rather than causes, hypertension [50,55].
ACE2 is a Negative Regulator of ACE in the Heart
As mentioned, ACE2-deficient mice show increased
tissue angiotensin II levels; they also show upregula-
tion of hypoxia genes in the heart and severe cardiac
dysfunction [7]. Indeed, the most striking phenotype of
the ACE2 mutant mice is of a profound decrease in
cardiac contractility [7]. Despite the elevated plasma
and heart angiotensin II levels, there is no evidence in
these mutant mice for structural alterations such as
myocardial fibrosis, hypertrophy or dilation. Rather
intriguingly, ACE2 mutant hearts resemble certain
kinds of defective heart found in human cases of coro-
nary artery disease and after bypass surgery — in par-
ticular, those cases referred to as ‘cardiac stunning’
[56] and ‘hibernation’ [57]. In these human diseases
and related animal models, chronic hypoxic conditions
lead to compensatory changes in myocyte metabolism
[56,58], upregulation of hypoxia-induced genes [59]
and reduced heart function [56,57,60].
Importantly, the cardiac dysfunction observed in
ACE2 mutant mice is completely reversed by a second
mutation that causes ACE deficiency [7]. Normal
cardiac function in ACE, ACE2 double mutant mice
suggests that a catalytic product of ACE triggers con-
tractile impairment in the absence of ACE2, supporting
the hypothesis that ACE2 is indeed a critical negative
regulator of the cardiac effects of the renin-angiotensin
system. So far, the mechanism by which the absence
of ACE2 induces impairment of cardiac contractility
has not been elucidated.
Given the moderately enhanced angiotensin II levels
in ACE2 mutant mice and the upregulation of hypoxia-
induced genes [7], it is tempting to speculate whether
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Figure 3. Domain structures of ACE,
ACE2 and collectrin.
Each protein is a type I integral protein with
a signal peptide, depicted in green, and
transmembrane domain in black. The zinc-
binding motif (HEMGH) repeats two times
in ACE and once in ACE2, and is located
within the homologous region denoted by
the yellow box. Regions of homology
between ACE2 and collectrin are denoted
by dark orange. The numbers refer to the
amino acids in each protein.
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the observed heart phenotype of ACE2 mutants is the
result of angiotensin II-mediated hypoperfusion, which
in turn is caused by vasoconstriction and endothelial
dysfunction [61,62]. Indeed, in vitro studies have
shown that angiotensin II directly induces hypoxia-
inducible factor-1α and VEGF in smooth muscle cells
and cardiomyocytes [63]. Furthermore, it has been
shown that angiotensin II causes endothelial dysfunc-
tion via the AT1A receptor and induction of oxidative
stress [61,64]. This view is supported by the fact that
ACE2 is expressed only in the vascular endothelium,
and not on cardiac myocytes [7]. Given the broad
specificity of ACE2 for various peptide systems, it is
not clear whether the elevated vascular tone of ACE2
mutant hearts is due simply to an unopposed effect of
angiotensin II, or whether alterations in the local
availability of other mediators also play a part (Figure
4). For example, angiotensin(1-7), which is cleaved from
angiotensin I by ACE2, acts as vasodilatatory peptide
on coronary arteries and preserves heart function and
coronary artery perfusion in rats after myocardial
infarction [65].
It thus appears that ACE2 does negatively regulate
the activated renin-angiotensin system, probably by
diverting the generation of the vasoactive peptide
angiotensin II towards inactive and vasodilatatory
peptides. Given that ACE2 is primarily expressed in
the kidneys and the heart only [6,7], it is intriguing to
speculate that ACE2 has been conserved during evo-
lution as a negative regulator of the renin-angiotensin
system in those organs whose vital function critically
depends on the maintenance of a constant blood
supply, even in the presence of a systemic vasopres-
sor response.
Perspectives
Studies of ACE2 single mutant and ACE, ACE2 double
mutant mice indicate that ACE2 is a negative regula-
tor of the renin-angiotensin system. It is not clear,
however, whether this function is mediated by ACE2’s
metallopeptidase or collectrin-like domain activities.
ACE2’s carboxypeptidase activity may limit the avail-
ability of angiotensin II, or may generate counterregu-
latory vasodilator peptide products. If the ACE2
mutant phenotype of decreased cardiac contractility
is indeed due to excess angiotensin II at the endothe-
lium–smooth muscle interface, one would expect that
ACE2, angiotensin II receptor double mutant mice will
turn out to have normal cardiac function. Given the
complexity of the involved systems, in vivo studies
with mutant mice or specific blocking agents appear
to be the most straightforward approach to further
elucidating the roles of ACE and ACE2 in regulating
the renin-angiotensin system.
If the physiological role of ACE does not involve its
metallopeptidase activity, it is conceivable that the
collectrin like-domain is involved. ACE2 and collectrin
are both upregulated upon tissue injury: ACE2 in heart
failure and collectrin in renal injury [60]. The
development of novel inhibitors specific to the collec-
trin-domain of ACE2, and the generation of collectrin-
deficient mice, should provide important information
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Figure 4. Simplified schematic representation of how ACE and ACE2 may regulate blood supply to coronary arteries.
Dotted arrows represent pathways, which may be important under pathophysiological conditions only.
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on the physiological roles of this protein domain and
address the question whether it is involved in the
renin-angiotensin system.
So far the ACE2 mutant mice have not added much
to our understanding of ACE2’s role in blood pressure
regulation. Key experiments remain to be done, such
as testing whether increasing ACE2 expression in
defined hypertensive rat strains ameliorates the
increased blood pressure. Polymorphisms of ACE or
angiotensin have not yet been clearly shown yet to be
associated with hypertension; analyses of small
nucleotide polymorphisms might reveal whether ACE2
polymorphisms are indeed associated with abnormal
blood pressure in some individuals. Moreover, ACE2
polymorphisms might be useful to assessing patients
for their future risk of developing heart failure or coro-
nary heart disease.
The role of hypoxia-inducible genes in ACE2 mutant
mice also needs to be addressed. Does upregulation of
those genes reflect an adaptive response to impaired
tissue oxygenation following a reduction in coronary
blood flow (Figure 4)? Is the upregulation of hypoxia-
induced genes coupled to pathways mediating cardiac
dysfunction [66,67] or is the impaired cardiomyocyte
contractility directly linked to angiotensin II-mediated
alterations to the intracellular calcium level [68,69]?
That ACE2 mutant mice show normal growth and
development, despite clearly impaired cardiac function,
suggests the existence of efficient compensatory
mechanisms which might be linked to the upregulation
of hypoxia-induced genes and their products.
To address the compensatory capacity of the renin-
angiotensin system in the absence of ACE2, ACE2
mutant mice should be exposed to various stresses,
including hypoxia, myocardial ischemia or systemic
inflammation. Such data may have important clinical
implications. For example, systemic inflammatory
response syndrome involves critically impaired perfu-
sion of kidneys, intestine and other tissues, as well as
cardiac dysfunction [70]. The question arises as to
what extent impaired cardiac function [71,72] and
renal failure [70] reflect endothelial dysfunction and
hypoperfusion which overwhelm the counter-regula-
tory capacity of the ACE2 system? If this is indeed the
case, it might define new goals in the approach
towards understanding and treatment of sepsis
mediated multi-organ failure.
We used to feel that we understood the renin-
angiotensin system. But the discovery of new enzymes,
new peptides and new regulatory pathways shows
that this system is actually far more complex than we
thought. This complexity will not only broaden our
knowledge on the evolution and biology of blood
pressure regulation, organ perfusion and salt/water
balance, but also offers a chance to develop new and
refined therapeutic strategies by aiming at new
enzymes, peptides, and receptors. The development
of ACE inhibitors and AT receptor blockers was just
the beginning.
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